vs
Side-by-side financial comparison of Everus Construction Group, Inc. (ECG) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $1.0B, roughly 1.0× Everus Construction Group, Inc.). Hologic runs the higher net margin — 17.1% vs 5.5%, a 11.6% gap on every dollar of revenue. On growth, Everus Construction Group, Inc. posted the faster year-over-year revenue change (33.2% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $23.5M). Over the past eight quarters, Everus Construction Group, Inc.'s revenue compounded faster (27.1% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
ECG vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.0B |
| Net Profit | $55.3M | $179.1M |
| Gross Margin | 11.6% | 56.0% |
| Operating Margin | 6.8% | 22.6% |
| Net Margin | 5.5% | 17.1% |
| Revenue YoY | 33.2% | 2.5% |
| Net Profit YoY | 60.4% | -10.9% |
| EPS (diluted) | $1.09 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.0B | ||
| Q3 25 | $986.8M | $1.0B | ||
| Q2 25 | $921.5M | $1.0B | ||
| Q1 25 | $826.6M | $1.0B | ||
| Q4 24 | $759.6M | $1.0B | ||
| Q3 24 | $761.0M | $988.0M | ||
| Q2 24 | $703.4M | $1.0B | ||
| Q1 24 | $625.7M | $1.0B |
| Q4 25 | $55.3M | $179.1M | ||
| Q3 25 | $57.0M | $187.2M | ||
| Q2 25 | $52.8M | $194.9M | ||
| Q1 25 | $36.7M | $-17.4M | ||
| Q4 24 | $34.5M | $201.0M | ||
| Q3 24 | $41.8M | $178.6M | ||
| Q2 24 | $39.0M | $194.5M | ||
| Q1 24 | $28.2M | $169.9M |
| Q4 25 | 11.6% | 56.0% | ||
| Q3 25 | 12.6% | 55.6% | ||
| Q2 25 | 13.0% | 56.3% | ||
| Q1 25 | 11.2% | 37.5% | ||
| Q4 24 | 11.4% | 56.8% | ||
| Q3 24 | 11.8% | 56.4% | ||
| Q2 24 | 12.6% | 55.4% | ||
| Q1 24 | 11.9% | 53.3% |
| Q4 25 | 6.8% | 22.6% | ||
| Q3 25 | 7.3% | 22.6% | ||
| Q2 25 | 7.9% | 24.9% | ||
| Q1 25 | 6.2% | -0.7% | ||
| Q4 24 | 6.1% | 22.5% | ||
| Q3 24 | 7.1% | 23.3% | ||
| Q2 24 | 7.3% | 24.1% | ||
| Q1 24 | 6.2% | 20.7% |
| Q4 25 | 5.5% | 17.1% | ||
| Q3 25 | 5.8% | 17.8% | ||
| Q2 25 | 5.7% | 19.0% | ||
| Q1 25 | 4.4% | -1.7% | ||
| Q4 24 | 4.5% | 19.7% | ||
| Q3 24 | 5.5% | 18.1% | ||
| Q2 24 | 5.5% | 19.2% | ||
| Q1 24 | 4.5% | 16.7% |
| Q4 25 | $1.09 | $0.79 | ||
| Q3 25 | $1.11 | $0.84 | ||
| Q2 25 | $1.03 | $0.86 | ||
| Q1 25 | $0.72 | $-0.08 | ||
| Q4 24 | $0.68 | $0.87 | ||
| Q3 24 | $0.82 | $0.75 | ||
| Q2 24 | $0.76 | $0.82 | ||
| Q1 24 | $0.55 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.4B |
| Total DebtLower is stronger | $281.5M | $2.5B |
| Stockholders' EquityBook value | $629.8M | $5.2B |
| Total Assets | $1.7B | $9.2B |
| Debt / EquityLower = less leverage | 0.45× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $553.0K | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $281.5M | $2.5B | ||
| Q3 25 | $285.1M | $2.5B | ||
| Q2 25 | $288.6M | $2.5B | ||
| Q1 25 | $292.1M | $2.5B | ||
| Q4 24 | $295.6M | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | $629.8M | $5.2B | ||
| Q3 25 | $573.0M | $5.0B | ||
| Q2 25 | $514.4M | $4.8B | ||
| Q1 25 | $460.2M | $4.6B | ||
| Q4 24 | $422.6M | $4.8B | ||
| Q3 24 | $453.3M | $5.1B | ||
| Q2 24 | $490.0M | $5.0B | ||
| Q1 24 | $464.3M | $4.8B |
| Q4 25 | $1.7B | $9.2B | ||
| Q3 25 | $1.6B | $9.0B | ||
| Q2 25 | $1.5B | $8.8B | ||
| Q1 25 | $1.4B | $8.5B | ||
| Q4 24 | $1.3B | $8.7B | ||
| Q3 24 | $1.3B | $9.2B | ||
| Q2 24 | — | $8.9B | ||
| Q1 24 | — | $8.7B |
| Q4 25 | 0.45× | 0.48× | ||
| Q3 25 | 0.50× | 0.50× | ||
| Q2 25 | 0.56× | 0.52× | ||
| Q1 25 | 0.63× | 0.55× | ||
| Q4 24 | 0.70× | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $48.2M | $229.9M |
| Free Cash FlowOCF − Capex | $23.5M | $215.2M |
| FCF MarginFCF / Revenue | 2.3% | 20.5% |
| Capex IntensityCapex / Revenue | 2.4% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.87× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $90.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.2M | $229.9M | ||
| Q3 25 | $76.2M | $355.1M | ||
| Q2 25 | $25.3M | $343.3M | ||
| Q1 25 | $7.1M | $169.4M | ||
| Q4 24 | — | $189.3M | ||
| Q3 24 | $78.9M | $367.0M | ||
| Q2 24 | — | $405.8M | ||
| Q1 24 | $21.9M | $292.4M |
| Q4 25 | $23.5M | $215.2M | ||
| Q3 25 | $65.7M | $341.4M | ||
| Q2 25 | $12.3M | $330.5M | ||
| Q1 25 | $-11.4M | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | $60.9M | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | $12.6M | $279.6M |
| Q4 25 | 2.3% | 20.5% | ||
| Q3 25 | 6.7% | 32.5% | ||
| Q2 25 | 1.3% | 32.3% | ||
| Q1 25 | -1.4% | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | 8.0% | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | 2.0% | 27.5% |
| Q4 25 | 2.4% | 1.4% | ||
| Q3 25 | 1.1% | 1.3% | ||
| Q2 25 | 1.4% | 1.3% | ||
| Q1 25 | 2.2% | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | 2.4% | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | 1.5% | 1.3% |
| Q4 25 | 0.87× | 1.28× | ||
| Q3 25 | 1.34× | 1.90× | ||
| Q2 25 | 0.48× | 1.76× | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 1.89× | 2.05× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | 0.77× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECG
| Commercial | $594.5M | 59% |
| Utility | $203.5M | 20% |
| Industrial | $82.8M | 8% |
| Institutional | $66.1M | 7% |
| Service And Other | $28.4M | 3% |
| Transportation | $24.2M | 2% |
| Renewables | $19.8M | 2% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
